A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine

NCT03963232 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Episodic Migraine

Interventions

DRUG: Galcanezumab
DRUG: Placebo

Sponsor

Eli Lilly and Company